Inicio>>Signaling Pathways>> PROTAC>> E3 Ligase Ligand-Linker Conjugate>>Lenalidomide-propargyl-C2-NH2 hydrochloride

Lenalidomide-propargyl-C2-NH2 hydrochloride

Catalog No.GC38808

El clorhidrato de lenalidomida-propargil-C2-NH2 incorpora un ligando de cereblon (CRBN) para la ubiquitina ligasa E3 y un enlazador. El clorhidrato de lenalidomida-propargil-C2-NH2 se puede utilizar para diseÑar el PROTAC MD-224.

Products are for research use only. Not for human use. We do not sell to patients.

Lenalidomide-propargyl-C2-NH2 hydrochloride Chemical Structure

Cas No.: 2489242-23-9

Tamaño Precio Disponibilidad Cantidad
1mg
111,00 $
Disponible
5mg
324,00 $
Disponible
10mg
510,00 $
Disponible
25mg
918,00 $
Disponible
50mg
1.530,00 $
Disponible
100mg
2.086,00 $
Disponible

Tel:(909) 407-4943 Email: sales@glpbio.com

Reseñas de cliente

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Lenalidomide-propargyl-C2-NH2 hydrochloride incorporates a cereblon (CRBN) ligand for the E3 ubiquitin ligase, and a linker. Lenalidomide-propargyl-C2-NH2 hydrochloride can be used to design the PROTAC MD-224 [1].

[1]. Li Y, et al. Discovery of MD-224 as a First-in-Class, Highly Potent, and Efficacious Proteolysis TargetingChimera Murine Double Minute 2 Degrader Capable of Achieving Complete and Durable TumorRegression. J Med Chem. 2019 Jan 24;62(2):448-466.

Reseñas

Review for Lenalidomide-propargyl-C2-NH2 hydrochloride

Average Rating: 5 ★★★★★ (Based on Reviews and 37 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Lenalidomide-propargyl-C2-NH2 hydrochloride

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.